Effects of Schedule I drug laws on neuroscience research and treatment innovation. (Q48463442)

11 February 2018

title

Effects of Schedule I drug laws on neuroscience research and treatment innovation. (English)

1 reference

11 February 2018

1 reference

David J Nutt

1

0 references

author name string

Leslie A King

series ordinal

2

1 reference

11 February 2018

David E Nichols

series ordinal

3

1 reference

11 February 2018

language of work or name

English

0 references

publication date

12 June 2013

1 reference

11 February 2018

Nature Reviews Neuroscience

published in

1 reference

11 February 2018

volume

14

1 reference

11 February 2018

page(s)

577-585

1 reference

11 February 2018

issue

8

1 reference

11 February 2018

https://scigraph.springernature.com/pub.10.1038/nrn3530

exact match

0 references

cites work

Development of a rational scale to assess the harm of drugs of potential misuse

1 reference

Drug harms in the UK: a multicriteria decision analysis

21 January 2018

1 reference

21 January 2018

1 reference

21 January 2018

1 reference

State of the art treatments for cannabis dependence

21 January 2018

1 reference

Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial

21 January 2018

1 reference

Multiple sclerosis and extract of cannabis: results of the MUSEC trial.

21 January 2018

1 reference

Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer

21 January 2018

1 reference

Human hallucinogenic drug research in the United States: a present-day case history and review of the process

21 January 2018

1 reference

The pharmacology of cannabinoid receptors and their ligands: an overview

21 January 2018

1 reference

Cannabinoid receptor localization in brain

21 January 2018

1 reference

Mitigation of post-traumatic stress symptoms by Cannabis resin: a review of the clinical and neurobiological evidence

21 January 2018

1 reference

Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment

21 January 2018

1 reference

Cannabidiol attenuates the appetitive effects of Delta 9-tetrahydrocannabinol in humans smoking their chosen cannabis

21 January 2018

1 reference

The psychoactive plant cannabinoid, Delta9-tetrahydrocannabinol, is antagonized by Delta8- and Delta9-tetrahydrocannabivarin in mice in vivo

21 January 2018

1 reference

Using dopamine research to generate rational cannabinoid drug policy

21 January 2018

1 reference

A method of conducting therapeutic sessions with MDMA.

21 January 2018

1 reference

Retracted article on dopaminergic neurotoxicity of MDMA

21 January 2018

1 reference

A review of the mechanisms involved in the acute MDMA (ecstasy)-induced hyperthermic response

21 January 2018

1 reference

An index of fatal toxicity for drugs of misuse.

21 January 2018

1 reference

Equasy — An overlooked addiction with implications for the current debate on drug harms

21 January 2018

1 reference

The safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study

21 January 2018

1 reference

Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study

21 January 2018

1 reference

Effects of MDMA on sociability and neural response to social threat and social reward

21 January 2018

1 reference

Is ecstasy an "empathogen"? Effects of ±3,4-methylenedioxymethamphetamine on prosocial feelings and identification of emotional states in others

21 January 2018

1 reference

Characterization of 3,4-methylenedioxymethamphetamine (MDMA) enantiomers in vitro and in the MPTP-lesioned primate: R-MDMA reduces severity of dyskinesia, whereas S-MDMA extends duration of ON-time.

21 January 2018

1 reference

The intriguing effects of ecstasy (MDMA) on cognitive function in mice subjected to a minimal traumatic brain injury (mTBI).

21 January 2018

1 reference

Seizure control as an indicator of therapeutic usefulness

21 January 2018

1 reference

Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials

21 January 2018

1 reference

Response of cluster headache to psilocybin and LSD.

21 January 2018

1 reference

Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance

21 January 2018

1 reference

Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later

21 January 2018

1 reference

Cortical circuits for perceptual inference

21 January 2018

1 reference

Serotonergic regulation of neuronal excitability in the prefrontal cortex

21 January 2018

1 reference

Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action

21 January 2018

1 reference

Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin

21 January 2018

1 reference

Implications for psychedelic-assisted psychotherapy: functional magnetic resonance imaging study with psilocybin.

21 January 2018

1 reference

Opioid dependence treatment: options in pharmacotherapy

21 January 2018

1 reference

The non-hallucinogen 2-bromo-lysergic acid diethylamide as preventative treatment for cluster headache: an open, non-randomized case series

21 January 2018

1 reference

Psychiatry, the pharmaceutical industry, and the road to better therapeutics

21 January 2018

1 reference

21 January 2018

Ketamine use: a review

1 reference

Methoxetamine: from drug of abuse to rapid-acting antidepressant

21 January 2018

1 reference

21 January 2018

1 reference

Can drugs be used to enhance the psychotherapeutic process?

31 March 2020

1 reference

Perverse effects of the precautionary principle: how banning mephedrone has unexpected implications for pharmaceutical discovery

31 March 2020

1 reference

Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder.

31 March 2020

1 reference

Htr2a Gene and 5-HT(2A) Receptor Expression in the Cerebral Cortex Studied Using Genetically Modified Mice

31 March 2020

1 reference

12 December 2020

Enhancing recovery after stroke with noradrenergic pharmacotherapy: a new frontier?

1 reference

12 December 2020

Introduction. The neurobiology of drug addiction: new vistas

1 reference

12 December 2020

Functional connectivity measures after psilocybin inform a novel hypothesis of early psychosis

1 reference

12 December 2020

Efficacy of ketamine in anesthetic dosage for the treatment of refractory complex regional pain syndrome: an open-label phase II study

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRN3530

1 reference

11 February 2018

PubMed ID

23756634

1 reference

11 February 2018